title: Successful treatment of rhinocerebral zygomycosis with a combination of caspofungin and liposomal amphotericin B.
abstract: Genera of the order Mucorales (Rhizopus, Mucor, Rhizomucor, Absidia, Apophysomyces, Cunninghamella, and Saksenaea) cause an angioinvasive infection called zygomycosis. Mortality rates can approach 100% depending on the patient's underlying disease and form of zygomycosis. We report here on the unusual case of a patient with acute myelogenous leukemia and zygomycosis unresponsive to monotherapy with liposomal amphotericin B, who responded favorably following the addition of the echinocandin caspofungin acetate.
authors.affiliation: Servicio de Hematologia, Hospital Universitario, Salamanca, Spain. lvazlo@usal.es
authors.forename: L
authors.initials: L
authors.lastname: Vazquez
authors.forename: J J
authors.initials: JJ
authors.lastname: Mateos
authors.forename: C
authors.initials: C
authors.lastname: Sanz-Rodriguez
authors.forename: E
authors.initials: E
authors.lastname: Perez
authors.forename: D
authors.initials: D
authors.lastname: Caballero
authors.forename: J F
authors.initials: JF
authors.lastname: San Miguel
mesh_terms: D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D000077336:Caspofungin; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D003646:Debridement; D004172:Diplopia / Q000209:etiology; D004359:Drug Therapy, Combination; D054714:Echinocandins; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage / Q000009:adverse effects; D016867:Immunocompromised Host; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000188:drug therapy; D055666:Lipopeptides; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage / Q000009:adverse effects; D009894:Opportunistic Infections / Q000188:drug therapy* / Q000209:etiology; D009916:Orbital Diseases / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology / Q000601:surgery; D010456:Peptides, Cyclic / Q000008:administration & dosage / Q000627:therapeutic use*; D012852:Sinusitis / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology / Q000601:surgery; D020096:Zygomycosis / Q000188:drug therapy* / Q000209:etiology / Q000601:surgery
chemical_list: D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D010456:Peptides, Cyclic; C068538:liposomal amphotericin B; D003561:Cytarabine; D000666:Amphotericin B; D008942:Mitoxantrone; D000077336:Caspofungin; D015255:Idarubicin